化痰解郁方联合舒乐安定治疗痰热内扰型失眠的临床观察(1)
【摘要】目的：分析化痰解郁方联合舒乐安定治疗痰热内扰型失眠的临床疗效。方法：选取我院治疗的96例痰热内扰型失眠患者，随机分为观察组和对照组各48例，对照组患者睡前服用舒乐安定，观察组患者采用化痰解郁方联合舒乐安定治疗，治疗4周后比较两组患者的匹兹堡睡眠质量指数问卷(PSQI)评分，治疗有效率和不良反应情况。结果：两组患者治疗前PSQI各因子评分比较，无显著性差异，P>0.05;治疗4周后，治疗组PSQI各因子评分以及总分均显著低于对照组，差异有统计学意义，P<0.05;治疗后观察组患者的总有效率93.75%，显著高于对照组77.08%，P<0.05;观察组患者总不良反应率4.17%，显著低于对照组16.67%，P<0.05。结论：化痰解郁方联合舒乐安定治疗痰热内扰型失眠临床效果显著，且不良反应较低。
【关键词】痰热内扰型;失眠;化痰解郁方;舒乐安定
[Abstract]Objective： To analyze the clinical efficacy of Huatanjieyu prescriptionson combined with Estazolamum in the treatment of disturbance of phlegm and heat insomnia.Methods： 96 patients with disturbance of phlegm and heat insomnia were selected and randomly divided into the observation group and control group，48 cases in each group. The control group patients took Estazolamum before going to bed， and the observation group patients were treated with Huatanjieyu prescriptionson combined with Estazolamum. After 4 weeks of treatment， the Pittsburgh Sleep Quality Index(PSQI) scores， total efficacy of the patients and adverse reactions of the two groups were compared. Results： There was no significant difference in PSQI score between the two groups before treatment， P>0.05; After 4 weeks of treatment， the score and total score of each factor in the treatment group were significantly lower than that of the control group， and the difference was statistically significant，P<0.05; The total efficacy of the patients in the post-treatment observation group was 93.75 %， which was significantly higher than that of the control group 77.08 %， P<0.05; The total adverse reaction rate was 4.17 %， significantly lower than the control group 16.67%， P<0.05.Conclusion： Huatanjieyu prescriptionson combined with Estazolamum was effective in the treatment of disturbance of phlegm and heat insomnia，and the adverse reaction is lower.
, http://www.100md.com
[Key words]Disturbance of phlegm and heat; insomnia; Estazolamum; Huatanjieyu prescriptionson
【中圖分类号】R224
【文献标识码】A
【文章编号】2095-6851(2019)11-240-01
失眠是一种常见的睡眠障碍性疾病，主要表现为入睡困难，深度睡眠不足，易醒，醒后不能再寐，或整夜噩梦不断。失眠不能消除人的疲劳感、恢复精力，白天出现头痛、注意力不能集中等，长期失眠可能会导致抑郁、焦虑和神经功能紊乱等，严重影响人们的正常工作和生活[1]。近年来，随着社会竞争的日益激烈，生活压力增大，失眠的发病率呈明显上升趋势。国内流行病学调查研究显示，我国成人失眠的发病率高达40%左右，失眠已经成为一个世界性的公共卫生问题[2]。中医学《内经》中称失眠为“目不瞑”、“不得眠”、“不寐”等。目前，目前临床上针对失眠发病机制进行的西医治疗方案，起效虽然较快，但副作用较大，且易产生依赖性。本研究对我院收治的痰热内扰型失眠给予化痰解郁方和舒乐安定联合治疗，取得了较好的临床效果，现将研究结果报道如下。
, 百拇医药
1 资料与方法
1.1 一般资料
选取我院2017年6月-2018年12月收治的96例痰热内扰型失眠痰热内扰型失眠患者作为研究对象，所有患者均符合西医和中医的诊断标准，西医诊断依据《中国精神病分类与诊断标准》[3]标准如下：入睡困难，睡眠维持障碍，整夜觉醒次数≥2次、早醒、睡眠质量下降;总睡眠时间减少，日间功能障碍等;中医参照《中医内科学》[4]痰热内扰型失眠诊断标准：心烦不寐，痰多口干，嗳气，胸闷脘痞，舌质红苔黄，兼口苦、目眩、溺黄便秘等。排除近期服用精神类药物或有药物过敏史的患者，妊娠期、哺乳期妇女以及伴有严重心肝肾疾病的患者，以上患者均签署知情同意书。将患者随机分为观察组和对照组各48例，其中观察组男21例，女27例，年龄25-65岁，平均年龄(52.79±6.47)岁，病程1-5年，平均病程(1.21±0.23)年;对照组男22例，女26例，年龄26-65岁，平均年龄(52.15±5.41)岁，病程1-5年，平均病程(1.24±0.25)年，两组患者在性别、年龄、病程等一般临床资料方面无显著性差异，具有可比性，P>0.05。, http://www.100md.com(肖文)
【关键词】痰热内扰型;失眠;化痰解郁方;舒乐安定
[Abstract]Objective： To analyze the clinical efficacy of Huatanjieyu prescriptionson combined with Estazolamum in the treatment of disturbance of phlegm and heat insomnia.Methods： 96 patients with disturbance of phlegm and heat insomnia were selected and randomly divided into the observation group and control group，48 cases in each group. The control group patients took Estazolamum before going to bed， and the observation group patients were treated with Huatanjieyu prescriptionson combined with Estazolamum. After 4 weeks of treatment， the Pittsburgh Sleep Quality Index(PSQI) scores， total efficacy of the patients and adverse reactions of the two groups were compared. Results： There was no significant difference in PSQI score between the two groups before treatment， P>0.05; After 4 weeks of treatment， the score and total score of each factor in the treatment group were significantly lower than that of the control group， and the difference was statistically significant，P<0.05; The total efficacy of the patients in the post-treatment observation group was 93.75 %， which was significantly higher than that of the control group 77.08 %， P<0.05; The total adverse reaction rate was 4.17 %， significantly lower than the control group 16.67%， P<0.05.Conclusion： Huatanjieyu prescriptionson combined with Estazolamum was effective in the treatment of disturbance of phlegm and heat insomnia，and the adverse reaction is lower.
, http://www.100md.com
[Key words]Disturbance of phlegm and heat; insomnia; Estazolamum; Huatanjieyu prescriptionson
【中圖分类号】R224
【文献标识码】A
【文章编号】2095-6851(2019)11-240-01
失眠是一种常见的睡眠障碍性疾病，主要表现为入睡困难，深度睡眠不足，易醒，醒后不能再寐，或整夜噩梦不断。失眠不能消除人的疲劳感、恢复精力，白天出现头痛、注意力不能集中等，长期失眠可能会导致抑郁、焦虑和神经功能紊乱等，严重影响人们的正常工作和生活[1]。近年来，随着社会竞争的日益激烈，生活压力增大，失眠的发病率呈明显上升趋势。国内流行病学调查研究显示，我国成人失眠的发病率高达40%左右，失眠已经成为一个世界性的公共卫生问题[2]。中医学《内经》中称失眠为“目不瞑”、“不得眠”、“不寐”等。目前，目前临床上针对失眠发病机制进行的西医治疗方案，起效虽然较快，但副作用较大，且易产生依赖性。本研究对我院收治的痰热内扰型失眠给予化痰解郁方和舒乐安定联合治疗，取得了较好的临床效果，现将研究结果报道如下。
, 百拇医药
1 资料与方法
1.1 一般资料
选取我院2017年6月-2018年12月收治的96例痰热内扰型失眠痰热内扰型失眠患者作为研究对象，所有患者均符合西医和中医的诊断标准，西医诊断依据《中国精神病分类与诊断标准》[3]标准如下：入睡困难，睡眠维持障碍，整夜觉醒次数≥2次、早醒、睡眠质量下降;总睡眠时间减少，日间功能障碍等;中医参照《中医内科学》[4]痰热内扰型失眠诊断标准：心烦不寐，痰多口干，嗳气，胸闷脘痞，舌质红苔黄，兼口苦、目眩、溺黄便秘等。排除近期服用精神类药物或有药物过敏史的患者，妊娠期、哺乳期妇女以及伴有严重心肝肾疾病的患者，以上患者均签署知情同意书。将患者随机分为观察组和对照组各48例，其中观察组男21例，女27例，年龄25-65岁，平均年龄(52.79±6.47)岁，病程1-5年，平均病程(1.21±0.23)年;对照组男22例，女26例，年龄26-65岁，平均年龄(52.15±5.41)岁，病程1-5年，平均病程(1.24±0.25)年，两组患者在性别、年龄、病程等一般临床资料方面无显著性差异，具有可比性，P>0.05。, http://www.100md.com(肖文)